Furthermore, bardoxolone methyl reduced cyclin D1 levels in tumors from xenograft and transgenic mouse models [17,41], and in tumor biopsies from patients enrolled in a phase 1 clinical trial (ClinicalTrials.gov ID: NCT00529438) [27]. The gene discussed is CCND1; the disease is neoplasm.